General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Half-Life (Normalesrd) Hours
36-70/No data
Plasma Protein Binding %
No data
Volume Of Distribution L/Kg
No data
Dose For Normal Renal Function
10-12 mg/m2 IV for 3-4 days
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
75% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: No data
References
Hollingshead LM, Faulds D. Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991; 42: 690-719. [PMID: 1723369] / Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993; 24: 275-88. [PMID: 8491056]
Toxicity Notes
Cardiotoxic. CHF. May cause prenal azotemia.